| Primary information |
|---|
| sequence ID | Seq_5628 |
| Peptide sequence | NGFKSHALQLNNRQIR |
| CancerPDF_ID | CancerPDF_ID38, CancerPDF_ID904, CancerPDF_ID1053, CancerPDF_ID1901, CancerPDF_ID9480, CancerPDF_ID9481, CancerPDF_ID11947, CancerPDF_ID12714, CancerPDF_ID12757, |
| PMID | 16896061,19795908,16395409,21136997,26379225,26379225,26992070,27058005,26282206 |
| Protein Name | Complement C4 precursor,Complement C4-B,Complement C4 precursor,Complement C4-B,Complement C4-A/Complement C4-B,Complement C4-A/Complement C4-B,Complement C4-B,Complement C4,Complement C4eB-like Isoform 1 |
| UniprotKB Entry Name | "CO4A_HUMAN,CO4B_HUMAN",CO4B_HUMAN,CO4A_HUMAN,CO4B_HUMAN,"CO4A_HUMAN,CO4B_HUMAN","CO4A_HUMAN,CO4B_HUMAN",CO4B_HUMAN,CO4A_HUMAN,CO4A_HUMAN |
| Fluid | Serum,Plasma,Serum,Serum,Plasma,Plasma,Serum,Serum,Serum |
| M/Z | 1895.99,632.67,1895.99,1895.02381,1896.03,1913.01,1895.0238,1896.068,1898.9 |
| Charge | 1,3,1,1,NA,NA,NA,NA,NA |
| Mass (in Da) | 1896.02,NA,NA,NA,NA,NA,NA,NA,NA |
| fdr | NA,NA,NA,NA,NA,NA,NA,NA,NA |
| Profiling Technique | MALDI-TOF,LC-MS,MALDI-TOF,LC-MS,MALDI-TOF,MALDI-TOF,LC-MS,MALDI-TOF,MALDI-TOF |
| Peptide Identification technique | Q/TOF MS/MS,MALDI-TOF/TOF,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,MALDI-TOF/TOF,MALDI-TOF/TOF,LC-MS/MS,LC-MS/MS,nano-LC/ESIeMS/MS |
| Quantification Technique | NA,LC-MRM (multiple reaction monitoring),NA,LC-ESI-MS,NA,NA,NA,NA,NA |
| Labelled/Label Free | Label Free,Labelled,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free |
| FDR | NA,less than 7%,less than 1 “5,NA,NA,NA,FDR 1 %,NA,NA |
| CancerPDF_ID | CancerPDF_ID38, CancerPDF_ID904, CancerPDF_ID1053, CancerPDF_ID1901, CancerPDF_ID9480, CancerPDF_ID9481, CancerPDF_ID11947, CancerPDF_ID12714, CancerPDF_ID12757, |
| p-Value | 1.00E-05,NA,9.14E-17,NA,1.00E-04,NA,NA,"less than 0.001,0.957,0.826",NA |
| Software | MASCOT,FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT (v 2.3),MASCOT (v 2.3),SEQUEST and Maxquant,Proteome Discoverer,BioworksBrowser |
| Length | 16,16,16,16,16,21,16,16,16 |
| Cancer Type | Metastatic thyroid carcinomas,Ductal adenocarcinoma of the pancreas (DAP),"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,Colorectal cancer,Colorectal cancer,Melanoma,Breast cancer,Cervical cancer |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,UniprotKB,UniprotKB,SwissProt Database,SwissProt Database,IPI Human Database (3.45) |
| Modification | NA,NA,NA,NA,NA,NA,NA,NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"42 normal, 28 patients","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy in training test set, In validation set 41 independent serum samples from patients with advanced prostate cancer (prostate 2 [PR2])",30 patients and 30 healthy controls,"94 patients with CRC, 23 with liver metastasis from CRC (histologically defined) and 34 subjects, which underwent colonoscopy and resulted negative","94 patients with CRC, 23 with liver metastasis from CRC (histologically defined) and 34 subjects, which underwent colonoscopy and resulted negative",8 cancer samples and 4 healthy samples," 28 were diagnosed with Breast cancer, 27 remained cancer-free with BRCA carrier. Of the remaining patients, 39 were diagnosed with sporadic breast cancer (SBC), and 38 were healthy volunteers (WT).",35 SCC patient |
| Regulation | NA,NA,"Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.27, 3.33 and 2.95 in prostate, bladder and breast cancer respectively",NA,"Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups.","Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups.","Present in 1 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples.","Upregulated with the fold change of 0.45 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.00, Upregulated in BC vs healthy with 0.968 fold change",Upregulated in Cervical squamous cell carcinoma vs healthy |
| Validation | Independent validation,NA,Independent validation,Leave One out Cross validation,NA,NA,na,NA,NA |
| Sensitivity | 95% on independent dataset,NA,97.5% on independent validation dataset,NA,NA,NA,NA,NA,100 % on traning data and 80% on validation dataset |
| Specificity | 95% on independent dataset,NA,NA,NA,NA,NA,NA,NA,100% on training data and 100% on validation dataset |
| Accuracy | NA,NA,97.5 % on validation dataset,NA,0.8446,NA,NA,NA,NA |
| Peptide Atlas | NA |
| IEDB | |